Ltr Pharma (ASX:LTP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Ltr Pharma (ASX:LTP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Webinar Presentation
First ROXUS Prescriptions Fulfilled in the United States
LTR Pharma fulfils first ROXUS prescriptions in the United States
Clinical and Commercial Update - Investor Webinar
SPONTAN Phase II Final Results
LTR Pharma completes FDA-aligned SPONTAN Phase II dataset ahead of U.S. regulatory work
Notice of Annual General Meeting/Proxy Form
Application for quotation of securities - LTP
Application for quotation of securities - LTP
Investor Presentation
LTR Expands Men's Health Portfolio with KYZATREX Pilot
FY26 Results Announcement
LTR Pharma advances clinical programs and secures US commercial pathway with strong FY26 results
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report to Shareholders
LTR Pharma advances intranasal ED therapies with US commercial deals and clinical progress, reports FY26 loss of A$14.16 million
SPONTAN Real-World Study Reports 93% Response
LTR Pharma's SPONTAN shows 93% response in convenience-seeking men and 64% in post-prostatectomy patients
Quarterly Activities/Appendix 4C Cash Flow Report
LTR Pharma advances clinical and commercial milestones with SPONTAN Phase II data and US ROXUS launch agreements
